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NVA237 is a once-daily inhaled long-acting muscarinic antagonist in development for the treat-
ment of COPD.
This randomized, double-blind, placebo-controlled, four-period, incomplete block crossover
study, with open-label active comparator (tiotropium), assessed the efficacy and safety of
NVA237. Patients (40 years; smoking history 10 pack-years) with stable moderate-to-severe
COPD (post-bronchodilator FEV1  30% and <80% predicted, FEV1/FVC < 0.7) received NVA237
12.5, 25, 50 or 100 mg, placebo, or tiotropium 18 mg once-daily for 7 days. The primary
endpoint was mean trough (23e24 h post-dose) FEV1 on Day 7. Secondary endpoints included
mean trough FEV1 on Day 1, and FEV1 and FVC at individual time points post-dose on Days 1 and
7. 83 patients (mean age 64.4 years; male 83.1%; mean COPD duration 6.7 years; mean post-
bronchodilator FEV1 1.5 L/52.7% predicted) were randomized; 78 completed. Mean trough
FEV1 on Day 7 and Day 1 was significantly higher with all active treatments versus placebo
(p < 0.05). NVA237 50 mg, 100 mg and tiotropium showed clinically relevant improvements
versus placebo on Day 7 (differences of 131, 142 and 127 mL, respectively; p < 0.0001) and
1 (differences of 121, 135 and 112 mL, respectively; p < 0.0001). On Day 1, but not Day 7,
FEV1 was significantly higher (p < 0.05) with NVA237 50 and 100 mg versus tiotropium from
5 min up to 2 and 4 h post-dose, respectively. All doses of NVA237 and tiotropium were well
tolerated.2 164 4139; fax: þ33 32 164 6350.
thune.fr (C. Verkindre).
0 Published by Elsevier Ltd.
Sustained 24-h efficacy of NVA237 in COPD patients 1483NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid
and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852).
ª 2010 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is only partially reversible
and usually progressive.1 The impact of the disease on an
individual patient depends on the severity of symptoms
(breathlessness and decreased exercise capacity, in partic-
ular), systemic effects, and presence of any comorbidities.1
COPD is a disease that is both preventable and treatable, but
it is frequently under-diagnosed and under-treated.1,2 It is
a leading cause of morbidity and mortality worldwide, and
represents a substantial economic and social burden that is
projected to increase over the coming decades.1,2
Pharmacotherapy for COPD is used to prevent and control
symptoms, reduce the frequency and severity of exacerba-
tions, improve health status, and improve exercise toler-
ance.1 Breathlessness is the hallmark symptom of COPD. It is
themain reasonmost patients seekmedical attention, and is
a major cause of COPD-related disability and anxiety.1
Bronchodilators are key to the symptomatic management
of COPD.1 Antimuscarinic agents, which include ipratropium
and tiotropium bromide, are one of the principal class of
bronchodilators used for the treatment of COPD. Short-
acting ipratropium3,4 and long-acting tiotropium5,6 have
both demonstrated efficacy in treating COPD symptoms.
NVA237 (a novel inhaled dry-powder formulation of
glycopyrronium bromide) is a once-daily long-acting
muscarinic antagonist (LAMA) in development for the
treatment of COPD. In preclinical studies, NVA237 demon-
strated high affinity and slow dissociation from muscarinic
receptors; an optimal profile for prolonged bronchodilation
in patients with COPD.7 Early single-dose8 and multiple-
dose9 studies have shown NVA237 once-daily provides sus-
tained 24-h bronchodilation with a rapid onset of action in
patients with moderate-to-severe COPD. In addition,
NVA237 is well tolerated with a good safety profile in this
patient population.8,9
The present study in patients with stable moderate-to-
severe COPD aimed to assess the efficacy and safety of four
separate doses of NVA237 (given via a single-dose dry-
powder inhaler [SDDPI]) in comparison with placebo and
active control (open-label tiotropium) to identify a sub-
therapeutic dose of NVA237 and to determine the optimal
dose for further clinical evaluation. The primary study
objective was to evaluate bronchodilatory efficacy in terms
of trough forced expiratory volume in 1 s (FEV1) following 7
days of treatment.
Methods
Patients
Included in this study were male or female adults aged 40
years with stable moderate-to-severe COPD10 anda smoking history of 10 pack-years (defined as: 20 ciga-
rettes/day for 10 years, or 10 cigarettes/day for 20 years,
etc.,). Patients must have had a post-bronchodilator
(following inhalation of 80 mg ipratropium bromide)
FEV1  30% and <80% of predicted normal values, and
a post-bronchodilator FEV1/forced vital capacity
(FVC) < 0.7. Predicted FEV1 was calculated according to
Quanjer predictive equations for non-Japanese patients,11
and according to Japanese Respiratory Society predictive
tables for Japanese patients.12
Study exclusion criteria included: requiring daily oxygen
therapy for chronic hypoxemia, hospitalization for exacer-
bation of airways disease in the 6 weeks prior to study start,
respiratory tract infection (or one that had resolved <6
weeks previously), history of asthma, prolonged QTc
interval at screening (or history of long QT syndrome),
history of malignancy within the previous 5 years (except
localized basal cell carcinoma of the skin), or any other
clinically relevant medical condition or laboratory abnor-
mality. Also excluded were patients unable to use any of
the study devices or to perform spirometry procedures,
those with history of an untoward reaction to any of the
study drugs, and women of child-bearing potential not using
an accepted form of contraception, pregnant women, or
nursing mothers.
Use of inhaled salbutamol as rescue medication was
permitted throughout the study (except immediately
before and during study visits, unless absolutely necessary).
Patients taking fixed combinations of inhaled corticoste-
roids (ICS) and long-acting b2-agonists were transferred to
the same dose of steroid contained in the fixed combination
and rescue medication for a period of 2 weeks prior to
starting study treatment. Patients on ICS monotherapy
continued on their pre-study ICS regimen. Use of the
following medications was not permitted during this study:
tiotropium (minimum washout prior to starting study
treatment: 7 days), short-acting anticholinergics (8 h),
fixed combinations of b2-agonists and ICS (48 h), long-acting
b2-agonists (48 h), short-acting b2-agonists other than those
prescribed in the study (6 h), any formulation of theoph-
ylline (7 days), or combinations of inhaled anticholinergics
and b2-agonists (24 h). Also prohibited were: any sympa-
thomimetic with potential bronchodilator effect, methyl-
xanthines, oral steroids for COPD, other anticholinergics,
b-blocking agents, or other investigational drugs. Inhaled or
nasal corticosteroids, cromoglycate, nedocromil and keto-
tifen were permitted if stabilized for 1 month prior to
screening.
Study design
This was a randomized, double-blind, placebo-controlled,
four-period, incomplete block crossover study, with an
open-label active comparator (tiotropium). The study
began with a screening period of up to 14 days to allow the
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current permitted medications were stable. Patients were
then randomized to one of 30 treatment sequences, each
comprising four 7-day treatment periods (once-daily
NVA237 12.5, 25, 50 or 100 mg given via SDDPI, placebo, or
open-label tiotropium 18 mg given via Handihaler; all
treatments were taken between 08:00 and 10:00 h) with
a 7-day washout between each treatment period. Patients
were assessed on Days 1 and 7 of each treatment period
and, in total, were required to attend the study centres for
18 visits. The study was conducted in hospital/specialist
respiratory clinics in Belgium, France and Japan.
A crossover study design was chosen since within-patient
variability in FEV1 is less than between-patient variability in
this patient population. This design therefore allowed the
total number of patients studied to be kept to a minimum.
An incomplete block design was chosen to reduce the
burden to patients of study visits and to reduce the number
of premature discontinuations (a complete block design
would have required patients to make an additional eight
visits during the study).
NVA237 12.5, 25, 50 and 100 mg were provided as
inhalation capsules in blisters. Placebo inhalation
capsules were equally matched in size, shape and colour
to NVA237 inhalation capsules. The active comparator,
tiotropium bromide 18 mg, was open-labelled. The inves-
tigator assessed treatment compliance at each visit via
capsule counts and information provided by the patient/
caregiver.
This study was conducted according to the ethical
principles of the Declaration of Helsinki. The protocol was
reviewed by the Independent Ethics Committee or Institu-
tional Review Board for each participating centre. All
patients provided written informed consent before
enrolling in the study.Study assessments and variables
Efficacy was assessed via spirometry. FEV1 and FVC were
measured at 45 and 15 min prior to the first dose of study
treatment (baseline), and at 5, 15 and 30 min, and 1, 2, 3, 4
and 5 h, 23 h 15 min, and 23 h 45 min post-dose on Days 1
and 7 of each treatment period. Three acceptable
manoeuvres were required to be performed for each time
point. The highest values measured were recorded, irre-
spective of whether or not they occurred on the same
curve. The primary efficacy variable was trough FEV1
(defined as the mean of the measurements taken at 23 h
15 min and 23 h 45 min post-dose) on Day 7. Secondary
efficacy variables included trough FEV1 on Day 1, and on
Days 1 and 7 the following variables: peak FEV1 (defined as
the maximum FEV1 value up to 5 h post-dose), standardized
(with respect to time) FEV1 area under the curve between
5 min and 5 h post-dose (AUC5 mine5 h), and FEV1 and FVC at
the individual time points post-dose. Onset of action was
assessed by comparing active treatments to placebo from
5 min post-dose on Day 1.
Safety assessments consisted of collecting adverse
events (including their severity and possible relationship to
study treatment), assessing vital signs, physical condition
and electrocardiograms (ECGs) throughout the study.Haematology, blood chemistry and urinalysis parameters
were assessed at screening, baseline and study completion.
Statistical analyses
The sample size was based on trough FEV1 at Day 7 and was
computed based on a formula for a balanced incomplete
block design (6 treatments, 4 periods, 30 sequences).13
Power was fixed at 80% to detect a treatment difference
versus placebo of 120 mL (an increase in FEV1 of
100e140 mL is generally considered to be clinically rele-
vant)14 at alpha 0.05/4, 2-sided (corrected by Dunnett’s
procedure for multiple-dose comparisons). Assuming
a dropout rate of 15% at least 73 patients needed to be
randomized, serving as their own controls.
The modified intent-to-treat (mITT) population included
all randomized patients who received at least one dose of
study medication; patients were analyzed according to the
treatment they received. The mITT population was used in
the analysis of all efficacy variables. The safety population
was defined as patients who took at least one dose of study
medication, and in this case was identical to the mITT
population. The safety population was used in the analysis
of all safety variables.
The primary efficacy variable (trough FEV1 on Day 7) was
analyzedusing the following analysis of covariance (ANCOVA)
model for a balanced incomplete (six-treatment four-period)
block design: trough FEV1 at Day 7 Z patient effect
(fixed) þ period effect þ treatment effect þ (period) base-
line FEV1 þ error. A similar ANCOVA model was used for all
other efficacy variables. The dose-response relationship was
analyzed using the trough FEV1 values on Day 7 with multiple
comparisons and modelling (MCP-Mod) procedures; the
minimum effective dose was calculated using the Emax
model. Safety variableswere summarizeddescriptively,with
clinically relevant or notable changes highlighted.
Results
Patients
In total, 83 patients were randomized into the study.
Seventy-eight (94%) completed the study, providing evalu-
able data for 51e55 patients per treatment group (Fig. 1).
The reasons for discontinuation were adverse events (AEs)
(n Z 3) and withdrawal of consent (n Z 2). Most patients
(4/5; 80.0%) discontinued whilst receiving placebo. The
majority of patients were male (69/83; 83.1%) and non-
Japanese (58/83; 69.9%). Other baseline demographic and
clinical characteristics are shown in Table 1.
Efficacy
The primary efficacy variable, mean trough FEV1 on Day 7,
was significantly higher with all active treatments
compared with placebo (p < 0.05; Fig. 2a). Similarly, the
mean trough FEV1 on Day 1 was significantly higher with all
active treatments versus placebo (p < 0.05; Fig. 2b).
Tiotropium significantly increased trough FEV1 compared
with the lowest dose of NVA237 (12.5 mg) on Day 1
Figure 1 Patient disposition. Since this was a crossover study, a patient could be counted in more than one of the treatment
groups; thus the sum of the treatment groups is greater than the number of patients randomized.
Sustained 24-h efficacy of NVA237 in COPD patients 1485(p < 0.05) and Day 7 (p < 0.05), and compared with NVA237
25 mg on Day 1 (p < 0.05).
On Day 7, both the 50 and 100 mg doses of NVA237
showed statistically significant improvements in mean
trough FEV1 versus placebo, which exceeded the pre-
defined threshold for clinical significance (i.e., >120 mL),
with differences of 131 and 142 mL, respectively
(p < 0.0001); the difference between tiotropium andTable 1 Patient baseline demographics and clinical
characteristics (safety population).
Total (n Z 83)
Age (years), mean (SD) 64.4 (9.0)
Range 45e80
Sex, n (%)
Male 69 (83.1)
Race, n (%)
Caucasian 58 (69.9)
Asian 25 (30.1)
Duration of COPD (years),
mean (SD)
6.7 (6.2)
Range 0e29
Smoking history, n (%)
Ex-smoker 43 (51.8)
Current smoker 40 (48.2)
Pack-years, mean (SD) 50.1 (29.6)
FEV1 pre-bronchodilator (L),
mean (SD)
1.3 (0.4)
FEV1 pre-bronchodilator
(% predicted), mean (SD)
46.0 (12.8)
FVC pre-bronchodilator (L),
mean (SD)
2.9 (0.6)
FEV1 post-bronchodilator (L),
mean (SD)
1.5 (0.4)
FEV1 post-bronchodilator
(% predicted), mean (SD)
52.7 (12.6)
FVC post-bronchodilator (L),
mean (SD)
3.3 (0.6)
FEV1 reversibility (%), mean (SD) 16.3 (13.2)
FEV1/FVC post-bronchodilator (%),
mean (SD)
46.6 (10.4)
SD Z standard deviation; COPD Z chronic obstructive pulmo-
nary disease; FEV1 Z forced expiratory volume in 1 s;
FVC Z forced vital capacity.placebo was 127 mL (p < 0.0001). On Day 1, the 50 and
100 mg doses of NVA237 also showed clinically relevant
improvements versus placebo, with differences of 121 and
135 mL, respectively (p < 0.0001); the difference between
tiotropium and placebo was 112 mL (p < 0.0001).
The results of a post-hoc analysis comparing Day 1 and
Day 7 mean trough FEV1 data for the 3 different NVA237
doses are shown in Table 2. On Day 7, the improvement in
mean trough FEV1 with 50 mg NVA237 was statistically
superior (pZ 0.0070) to 12.5 mg NVA237, although it failed
marginally to show statistical significance versus 25 mg
NVA237 (p Z 0.0537). In addition, on Day 1 50 mg NVA237
was statistically superior to 25 mg (pZ 0.0009) and 12.5 mg
(p < 0.0001). However, the improvement in mean trough
FEV1 on Day 7 with 25 mg NVA237 was not statistically
superior to 12.5 mg. Responder rates (difference of
120 mL in trough FEV1 relative to placebo) for the NVA237
50, 25, and 12.5 mg groups were 61, 43, and 28%,
respectively.
Serial FEV1 data are shown in Fig. 3. FEV1 over 24 h after
dosing on Day 7 was significantly improved for all active
treatments compared with placebo (p < 0.05) (Fig. 3a).
There were no statistically significant differences between
any of the NVA237 doses and tiotropium, with the exception
of three post-dose time points (23 h 15 min and 23 h 45 min
in the NVA237 12.5 mg group, and 5 h in the NVA237 25 mg
group).
On Day 1, there were significant increases in FEV1 with
NVA237 versus placebo (p < 0.05) that were sustained
from 5 min to 24 h post-dose, apart from for the 12.5 mg
dose at a single time point (23 h 45 min). FEV1 was
significantly (p < 0.05) higher with NVA237 than with
tiotropium at the following post-dose time points: NVA237
25 mg, from 5 min to 1 h; NVA237 50 mg, 5 mine2 h; NVA237
100 mg, 5 mine4 h. Conversely, FEV1 was significantly
higher with tiotropium than with NVA237 at the following
post-dose time points: NVA237 12.5 mg, from 4 h to 23 h
45 min; NVA237 25 mg, from 23 h 15 mine23 h 45 min
(Fig. 3b).
All active treatments showed statistically significant
improvements over placebo on Days 1 and 7 for peak FEV1
and standardized FEV1 AUC5 mine5 h (p < 0.05; Table 3). On
Day 1, values for both the 50 and 100 mg doses of NVA237
were significantly greater than those for tiotropium
(p < 0.05).
Serial measurements of FVC followed a similar pattern
to FEV1 (data not shown).
Figure 2 Trough FEV1 treatment contrasts (active versus placebo and NVA237 versus tiotropium; least square means, 95%
confidence intervals) after (a) 7 days and (b) 1 day of treatment (mITT population). FEV1 Z forced expiratory volume in 1 s;
mITT Z modified intent-to-treat.
Table 2 NVA237 dose comparison of mean trough FEV1 (L) (mITT population).
NVA237 dose comparison LS mean SE 95% CI p value
Day 1
NVA237 50 mgNVA237 25 mg 0.063 0.019 (0.026, 0.099) 0.0009
NVA237 50 mgNVA237 12.5 mg 0.083 0.018 (0.047, 0.119) <0.0001
NVA237 25 mgNVA237 12.5 mg 0.020 0.018 (0.016, 0.057) 0.2663
Day 7
NVA237 50 mgNVA237 25 mg 0.042 0.021 (0.001, 0.084) 0.0537
NVA237 50 mgNVA237 12.5 mg 0.057 0.021 (0.016, 0.098) 0.0070
NVA237 25 mgNVA237 12.5 mg 0.015 0.021 (0.026, 0.057) 0.4685
LS Z least squares; SE Z standard error of the mean; CI Z confidence interval.
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Figure 3 Twenty-4-h profile of least square means of FEV1 on (a) Day 7 and (b) Day 1 of treatment (mITT population). a) All
treatments were significant (p < 0.05) versus placebo; #p < 0.05 versus tiotropium b) All treatments were significant (p < 0.05)
versus placebo at each post-dose time point (except NVA237 12.5 mg at 23 h 45 min); #p < 0.05 versus tiotropium. FEV1 Z forced
expiratory volume in 1 s; mITT Z modified intent-to-treat.
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The most commonly reported AE during the study was
headache (4/55 patients [7.3%] with NVA237 12.5 mg, 2/54
patients [3.7%] with tiotropium, and one patient with each
of the other NVA237 doses; Table 4). Most AEs were mild
and transient and appeared not to be dose related.
One serious adverse event (SAE) was reported: gastric
cancer diagnosed in a patient taking NVA237 50 mg (not
suspected to be drug related); this patient was dis-
continued from the study. Two other patients experi-
enced AEs that led to premature discontinuation (COPD
exacerbations, not suspected to be drug related), one
during treatment with NVA237 25 mg and one with NVA237
100 mg.There were no clinically relevant changes during the
study in haematology, biochemistry or urinalysis
parameters.
Mean pulse rate tended to decrease slightly with all
treatments (including tiotropium and placebo), with the
maximum decreases occurring approximately 1e3 h after
dosing. There were no occurrences of pulse rate 40 bpm.
The incidence of elevated pulse rate (90 bpm) was
generally similar across the treatments.
There were no clinically relevant changes in mean
systolic or diastolic blood pressure. The number of patients
who had notable values for systolic blood pressure
(140 mmHg) with NVA237 was similar to or lower than with
placebo or tiotropium. For diastolic blood pressure, three
patients had values 50 mmHg (two taking NVA237 12.5 mg
Table 3 Least square mean (SE) peak FEV1 and standardized FEV1 AUC5 mine5 h (mITT population).
NVA237 Placebo
(n Z 55)
Tiotropium
(n Z 55)12.5 mg (n Z 55) 25 mg (n Z 51) 50 mg (n Z 53) 100 mg (n Z 54)
Peak FEV1 (L)
Day 1 1.49 (0.01)a 1.53 (0.01)a 1.55 (0.01)a,b 1.56 (0.01)a,b 1.36 (0.01) 1.51 (0.01)a
Day 7 1.53 (0.02)a 1.54 (0.02)a 1.56 (0.02)a 1.56 (0.02)a 1.33 (0.02) 1.55 (0.02)a
Standardized FEV1 AUC5 mine5 h (L)
Day 1 1.41 (0.01)a 1.45 (0.01)a 1.47 (0.01)a,b 1.50 (0.01)a,b 1.29 (0.01) 1.44 (0.01)a
Day 7 1.45 (0.01)a 1.46 (0.02)a 1.48 (0.01)a 1.49 (0.01)a 1.26 (0.01) 1.47 (0.01)a
SE Z standard error; FEV1 Z forced expiratory volume in 1 s; AUC5 mine5 h Z area under the curve from 5 min to 5 h post-dose;
mITT Z modified intent-to-treat.
Note: results are based on patients with available data; tiotropium mITT population is 55 patients and safety population is 54 patients
because one patient erroneously received tiotropium in two periods.
a p < 0.05 versus placebo.
b p < 0.05 versus tiotropium.
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with elevated diastolic blood pressure (90 mmHg) was
lower with all doses of NVA237 (27.5e38.9%) than with
tiotropium (50.9%), and was similar to placebo (36.4%).
The incidence of notable QTc interval values (Frider-
icia’s formula; >440 ms for males and >460 ms for females)
was low, with values lower for all active treatment groups
(0e3.8%) than placebo (5.5%). No patient had an increase in
QTcF interval of >60 ms from pre-dose to post-dose, or
a clinically significant abnormality in their post-dose ECG.
Discussion
NVA237 is a once-daily inhaled LAMA in development for the
treatment of COPD. The efficacy and safety of four sepa-
rate doses of NVA237 (12.5, 25, 50 or 100 mg given via SDDPI)
in comparison with placebo and active control (open-label
tiotropium 18 mg given via Handihaler) in patients with
stable moderate-to-severe COPD were assessed in the
present study.
The results indicate that following 7 days of once-daily
treatment all doses of NVA237 showed sustained 24-h
bronchodilation, as evidenced by significantly higher mean
trough (23e24 h post-dose) FEV1 compared with placebo
(p < 0.05). Furthermore, the improvements in mean trough
FEV1 on Day 7 with NVA237 50 and 100 mg were clinically
relevant (i.e., >120 mL versus placebo). Similar results
were obtained on Day 1. The results also indicate that theTable 4 The total and most common (>2% in any NVA237 grou
Patients, n (%) NVA237
12.5 mg (n Z 55) 25 mg (n Z 51) 50 m
Total 11 (20.0) 11 (21.6) 11 (
Headache 4 (7.3) 1 (2.0) 1 (
Rhinitis 0 3 (5.9) 0
Cough 3 (5.5) 0 0
Nasopharyngitis 2 (3.6) 2 (3.9) 0
Toothache 0 0 2 (onset of NVA237 effect was rapid: on both Days 1 and 7, all
doses of NVA237 showed statistically significant improve-
ments in FEV1 values compared with placebo from 5 min
post-dose (p < 0.05). These results are consistent with
earlier findings that once-daily NVA237 provides sustained
24-h bronchodilation with a rapid onset of effect.8,9
One purpose of this study was to identify a suitable
NVA237 dose for future studies. NVA237 demonstrated
a clear dose-response relationship in this study, analysis of
which estimated the minimum effective dose (i.e., the dose
to result in a 120 mL increase in trough FEV1 on Day 7) to be
42 mg once-daily. Doses greater than this (up to 100 mg
once-daily) were not associated with any tolerability or
safety concerns.
NVA237 50 and 100 mg and tiotropium appeared similar in
terms of bronchodilatory efficacy and duration of action.
However, the data indicate that NVA237 had a more rapid
onset of action than tiotropium: on Day 1, FEV1 was
significantly higher with NVA237 25, 50 and 100 mg versus
tiotropium from 5 min up to 1 h post-dose (p < 0.05). Peak
FEV1 and standardized FEV1 AUC5 mine5 h were also signifi-
cantly greater with NVA237 50 and 100 mg than with
tiotropium on Day 1 (p < 0.05). The finding of a more rapid
onset of action with NVA237 than with tiotropium is
consistent with previous observations from a multiple-dose
study,9 and may represent a benefit to patients in terms of
them feeling an immediate effect with treatment. In
a previous study, tiotropium reached pharmacodynamicp) adverse events reported (safety population).
Placebo
(n Z 55)
Tiotropium
(n Z 54)g (n Z 53) 100 mg (n Z 54)
20.8) 8 (14.8) 7 (12.7) 7 (13.0)
1.9) 1 (1.9) 0 2 (3.7)
0 1 (1.8) 0
1 (1.9) 2 (3.6) 0
0 1 (1.8) 0
3.8) 0 0 1 (1.9)
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Sustained 24-h efficacy of NVA237 in COPD patients 1489steady state (in terms of both trough and acute broncho-
dilatory response) within 1 week of treatment.5 This might
explain why on Day 7 of the present study there were no
longer any relevant differences in FEV1 between NVA237
and tiotropium at the early time points post-dose.
NVA237 was well tolerated with a good overall safety
profile. No safety signals of concern were identified from
the AE data, and this is consistent with previous findings
reporting the good overall safety profile of NVA237.15 In
our study, there was no observable dose-response rela-
tionship between NVA237 and AEs, and no increase in
COPD-related AEs compared with placebo or tiotropium.
No single AE was reported by more than 8% of patients
with any particular treatment. Dry mouth, which has
previously been reported in 15e16% of patients taking
tiotropium,5,6 was not observed in the present study. This
may be due to the short treatment duration in this study,
as a median time of onset of dry mouth of 4 weeks has
previously been reported with ipratropium and tio-
tropium.5 Ongoing longer-term studies will assess the
incidence of dry mouth with NVA237. Laboratory findings,
vital signs and ECG observations were generally
unchanged during the study. These safety and tolerability
observations are in-line with those from earlier NVA237
studies.8,9
The results of the present study support the continued
development of once-daily NVA237 for the treatment of
patients with COPD. However, further investigations are
warranted since, in addition to spirometric variables, there
are other outcome parameters e such as improvements in
symptoms, exercise capacity, and quality of life e that are
relevant to the patient.
In conclusion, NVA237 was effective and well tolerated
for the treatment of moderate-to-severe COPD at all
doses compared with placebo, and demonstrated rapid
and sustained 24-h bronchodilation. Additionally, the
onset of action may be more rapid with NVA237 (50 and
100 mg) than tiotropium, which might represent a benefit
to patients.
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